London-based Oyster Therapeutics raised $60 million in Series A-2 funding, led by 4BIO Capital with backing from Eli Lilly, to advance its brain-penetrating targeted protein degrader platform. Oyster's SELFTAC technology splits drug molecules to cross the blood-brain barrier before reassembling to selectively clear toxic tau protein aggregates while leaving healthy tau intact. The financing supports clinical development of an oral alternative to injectable Alzheimer's antibody treatments like Kisunla and Leqembi.
Series A-2 funding details
- ▪London-based Oyster Therapeutics raised $60 million in Series A-2 funding to advance its preclinical brain-penetrating small molecule degrader research in Alzheimer's disease
- ▪Existing investors Syncona, Oxford Science Enterprises, Mission BioCapital, and MGB Ventures participated in Oyster Therapeutics' Series A-2 financing following a $33 million Series A in 2022
- ▪Oyster Therapeutics' $60 million Series A-2 round was led by 4BIO Capital, with participation from new investors Eli Lilly, Actium Group, CE Ventures, and TOHO Ventures
- ▪Oyster Therapeutics was formerly known as Kesmalea Therapeutics before rebranding alongside its $60 million Series A-2 funding announcement
SELFTAC technology and platform applications
- ▪Oyster Therapeutics was founded on research by medicinal chemist Harry Finch, who studied methods to overcome the large size limitations of targeted protein degraders during the COVID-19 pandemic
- ▪Oyster Therapeutics' technology disassembles a heterobifunctional protein degrader into two smaller molecules to pass through the intestinal wall and blood-brain barrier before reassembling inside target cells
Competitor RNA therapies and Oyster's approach
- ▪Biogen reported preliminary Phase 2 data in May 2026 showing tau reduction and cognitive benefit for its antisense oligonucleotide diranersen, though the trial missed its main dose-response goal at week 76
- ▪Oyster Therapeutics CEO Rob Johnson noted that RNA-based tau therapies non-selectively reduce levels of all tau protein, including healthy tau critical for neuron function
- ▪Arrowhead Pharmaceuticals reported interim Phase 1/2 data showing its siRNA therapy ARO-MAPT reduced tau levels in healthy volunteers
Alzheimer's treatment strategies
- ▪Approved Alzheimer's therapies Kisunla from Eli Lilly and Leqembi from Biogen and Eisai target amyloid protein plaques but offer only modest cognitive effects without stopping disease progression
- ▪Oyster Therapeutics CEO Robert Johnson stated that combining amyloid- and tau-targeting therapies might be key to fully treating Alzheimer's disease and other neuroinflammatory conditions
Targeted protein degrader challenges
- ▪Oyster Therapeutics CEO Rob Johnson noted that many degrader programs in the biopharmaceutical industry have been shelved due to an inability to overcome the size problem of those molecules
- ▪First-generation targeted protein degraders reached commercial markets for oncology in 2026 and are expanding into immunology, though brain delivery remains constrained by blood-brain barrier permeability
Story comments
Loading comments…